Myocardial Ischemia: The Potential Therapeutic Role of Prostacyclin and Its Analogues

  • P. J. Simpson
  • B. R. Lucchesi

Abstract

Prostacyclin (PGI2) and its stable analogues are potentially valuable therapeutic agents in at least three important cardiovascular disorders. By virtue of the vasodilatory properties of these agents and their ability to inhibit platelet activation by virtually all aggregating stimuli PGI2 analogues may be effective anti–thrombotic agents in vivo. Romson et al. [41] demonstrated that PGI2 infusion in the anesthetized dog was effective in preventing coronary artery thrombosis. Furthermore, administration of low dose PGI2 concomittantly with a phosphor–diesterase inhibitor, potentiated the antithrombotic effects of PGI2 without the decrease in blood pressure associated with higher doses of the prostanoid [43, 44].

Keywords

Superoxide Explosive Choline Catecholamine Cardiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Araki H, Lefer AM (1980) Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res 47: 757–763PubMedGoogle Scholar
  2. 2.
    Bannister JV, Bannister WH, Hill HAO, Thornally PI (1982) Enhanced production of hydroxyl radicals by the xanthine-xanthine oxidase reaction in the presence of lactoferrin. Biochim Biophys Acta 715–116–120PubMedCrossRefGoogle Scholar
  3. 3.
    Bednar M, Smith B, Pinto A, Mullane KM (1985) Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 57: 131–141PubMedGoogle Scholar
  4. 4.
    Bednar M, Smith B, Pinto A, Mullane KM (1985) Neutrophil depletion suppresses 111–in- dium-labelled platelet accumulation in infarcted myocardium. J Cardiovasc Pharmacol 7: 906–912PubMedCrossRefGoogle Scholar
  5. 5.
    Boveris A, Chance B (1973) The mitochondrial generation of hydrogen peroxide. Biochem J 134: 707–716PubMedGoogle Scholar
  6. 6.
    Chance B, Sies H, Boveris A (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527–605PubMedGoogle Scholar
  7. 7.
    Egan KR, Gale PH, Kuehl FA (1974) Reduction of hydroperoxides in the prostaglandin biosynthetic pathway by a microsomal peroxidase. J Biol Chem 254: 3295–3302Google Scholar
  8. 8.
    Fantone JC, Kunkel SL, Ward PA, Zurier RB (1980) Suppression by prostaglandin Ei of vascular permeability induced by vasoactive mediators. J Immunol 125: 2591–2595PubMedGoogle Scholar
  9. 9.
    Fantone JC, Kunkel SL, Ward PA, Zurier RB (1981) Suppression of human polymorpho-nuclear leukocyte function after intravenous infusion of PGE1 Prostaglandins Leukotrienes Med 2: 195Google Scholar
  10. 10.
    Fantone JC, Marasco WA, Elgas LJ, Ward PA (1983) Anti-inflammatory effects of prostaglandin Ej: In vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil. J Immunol 130: 1495–1497Google Scholar
  11. 11.
    Fantone JC, Kinnes DA (1983) Prostaglandin E1 and prostaglandin I2 modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun 113: 506–512PubMedCrossRefGoogle Scholar
  12. 12.
    Fantone JC, Kunkel SL, Zurier RB (1984) Effects of prostaglandins on in vivo immune and inflammatory reactions. In: Goodwin J (ed) Prostaglandins and immunity. Martinez and Nijhoff, Boston, pp 123–146Google Scholar
  13. 13.
    Fantone JC, Marasco WA, Elgas LJ, Ward PA (1984) Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol 115: 9–16PubMedGoogle Scholar
  14. 14.
    Fantone JC, Ward PA (1982) Role of oxygen derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 107: 397–418Google Scholar
  15. 15.
    Gobel FL, Nordsstrom LA, Nelson RR, Jorgenson CR, Wang Y (1978) The rate pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation 57: 549–556PubMedGoogle Scholar
  16. 16.
    Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl F (1983) Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci USA 80: 4349–4353PubMedCrossRefGoogle Scholar
  17. 17.
    Hearse DJ, Humphrey SM, Nayler WG, Slade A, Border D (1975) Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 7: 315–324PubMedCrossRefGoogle Scholar
  18. 18.
    Heyndricks GR, Baig H, Neilens D, Leusen I, Fishbein MC, Vatner SF (1978) Depression of regional blood flow and wall thickening after brief coronary occlusion. Am J Physiol 234: H653–H659Google Scholar
  19. 19.
    Jennings RB, Ganote GB, Kloner RA, Whalen DA, Hamilton DG (1975) Explosive cell swelling of myocardial cells irreversibly injured by transmural ischemia. In: Fleckenstein A, Rona G (eds) Pathophysiology and morphology of myocardial cell alteration. University Park Press, Baltimore (Recent advances in studies on cardiac structure and metabolism, vol 6 )Google Scholar
  20. 20.
    Jennings RB, Reimer K (1979) Biology of experimental acute myocardial ischemia and in–farction. In: Hearse DJ, deLeiris J (eds) Enzymes in cardiology: diagnosis and research. Wiley, Chichester, pp 21–57Google Scholar
  21. 21.
    Johnson KJ, Varani J, Oliver J, Ward PA (1979) Immunologic vasculitis in beige mice with deficiency of leukocytic neutral proteases. J Immunol 122: 1807–1812PubMedGoogle Scholar
  22. 22.
    Johnson KJ, Ward PA (1981) Role of oxygen metabolites in immune complex injury of lung. J Immunol 122: 1807–1812Google Scholar
  23. 23.
    Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR (1984) Canine myocardial reperfusion injury: its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 54: 277–285PubMedGoogle Scholar
  24. 24.
    Jolly SR, Schumacher WA, Kunkel SL, Abrams GD, Liddicoat J, Lucchesi BR (1985) Platelet depletion in experimental myocardial infarction. Basic Res Cardiol 80: 269–279PubMedCrossRefGoogle Scholar
  25. 25.
    Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC (1981) Dissimilar effects of prostacyclin, prostaglandin Ex and prostaglandin E2, on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49: 685–700PubMedGoogle Scholar
  26. 26.
    Kloner R, Braunwald E (1980) Observations on experimental myocardial ischemia. Cardiovasc Res 14: 371–395PubMedCrossRefGoogle Scholar
  27. 27.
    Lefer AM, Ogletree MNL, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic GP (1978) Prostacyclin: a potentially valuable agent for preserving ischemic myocardial tissue in acute myocardial ischemia. Science 200: 52–54PubMedCrossRefGoogle Scholar
  28. 28.
    Lucchesi BR, Romson JL, Jolly SR (1984) Do leukocytes influence infarct size? In: Hearse DJ, Yellon DM (eds) Therapeutic approaches to myocardial infarct size limitation. Raven, New York, pp 219–248Google Scholar
  29. 29.
    Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Braunwald E (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 53: 67–82Google Scholar
  30. 30.
    Marone G, Thomas LC, Lichtenstein LM (1980) The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol 125: 2277–2283PubMedGoogle Scholar
  31. 31.
    McCord JM, Fridovitch I (1969) Superoxide dismutase: an enzymic function for erythrocu-prein (hemocuprein). J Biol Chem 244: 6049–6055PubMedGoogle Scholar
  32. 32.
    Meerson FZ, Gagan VE, Kozlow YuP, Belkin LM, Arkipenko YV (1982) The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res Cardiol 77:465–480PubMedCrossRefGoogle Scholar
  33. 33.
    Melin JA, Becker LC (1983) Salvage of ischemic myocardium by prostacyclin during experimental myocardial infarction. J Am Coll Cardiol 2: 279–286PubMedCrossRefGoogle Scholar
  34. 34.
    Nicholson NS, Smith SL, Taite BB, Krueger A, Fuller GC (1985) Evaluation of a stable 5-F prostacyclin analogue as an antithrombotic agent in hemodialysis. Submitted to Drugs Under Experimental ResearchGoogle Scholar
  35. 35.
    Ogletree ML, Lefer AM (1978) Prostaglandin-induced preservation of the ischemic myocardium. Circ Res 42: 218–224PubMedGoogle Scholar
  36. 36.
    Ogletree ML, Lefer AM, Smith JB, Nicolaou KC (1979) Studies on the protective effects of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 56: 95–103PubMedCrossRefGoogle Scholar
  37. 37.
    Opie LH (1979) Energy metabolism of heart muscle during hypoxia and ischemia. In: Gross F (ed) Modulation of sympathetic tone in the treatment of cardiovascular diseases. Huber, Bern, p 43Google Scholar
  38. 38.
    Otani H, Tanaka H, Inoue T, Umemoto M, Omoto K, Tanaka K, Sato T, Osako T, Masuda A, Nonoyama A, Kagawa T (1984) In vitro study on contribution of oxidative metabolism of isolated rabbit heart mitochondria to myocardial reperfusion injury. Circ Res 55:168– 175Google Scholar
  39. 39.
    Rao PS, Mueller HS (1983) Lipid peroxidation and acute myocardial ischemia. Adv Exp Med Biol 161: 347–363PubMedGoogle Scholar
  40. 40.
    Rivkin I, Rosenblatt J, Becker EI (1975) The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal neutrophils. J Immunol 115: 1126–1134PubMedGoogle Scholar
  41. 41.
    Romson JL, Haack DW, Abrams GD, Lucchesi BR (1981) Prevention of occlusive coronary artery thrombosis by prostacyclin infusion in the dog. Circulation 64: 906–914PubMedCrossRefGoogle Scholar
  42. 42.
    Romson JL, Hook BG, Rigot VH, Schork MA, Swanson DP, Lucchesi BR (1982) The effects of ibuprofen on accumulation of Ill–indium labeled platelets and leukocytes in experimental myocardial infarction. Circulation 66: 1002–1011PubMedCrossRefGoogle Scholar
  43. 43.
    Romson JL, Hook BG, Lucchesi BR (1983) Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 227: 288–294PubMedGoogle Scholar
  44. 44.
    Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR (1983) Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67: 1016–1023PubMedCrossRefGoogle Scholar
  45. 45.
    Roos D, Weening RS, Wyss SR (1980) Protection of human neutrophils by endogenous catalase: studies with cells from catalase deficient individuals. J Clin Invest 65: 1515–1522PubMedCrossRefGoogle Scholar
  46. 46.
    Schror K, Addicks K, Darius H, Ohlendorf R, Rosen P (1981) PGI2 inhibits ischemia induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res 21: 175–180PubMedCrossRefGoogle Scholar
  47. 47.
    Schror K, Ohlendorf R, Darius H (1981) Beneficial effects of a new carbacyclin derivative (ZK 36374) in acute myocardial ischemia. J Pharmacol Exp Ther 219: 243–249PubMedGoogle Scholar
  48. 48.
    Schror K, Darius H, Ohlendorf R, Matzky R, Klaus W (1982) Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36375). J Cardiovasc Pharmacol 4: 554–561PubMedGoogle Scholar
  49. 49.
    Schumacher WA, Lee EC, Lucchesi BR (1985) Augmentation of streptokinase thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 7: 739–746PubMedCrossRefGoogle Scholar
  50. 50.
    Simpson PS, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR (1986) Prostacyclin protects ischemic-reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J (in press)Google Scholar
  51. 51.
    Smith RJ, Iden SS (1980) Pharmacological modulation of chemotactic factor-elicited release of granule-associated enzymes from human neutrophils. Biochem Pharmacol 29:2389– 2395PubMedCrossRefGoogle Scholar
  52. 52.
    Smith EF, Lefer AM (1981) Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion: efficacy of the nonsteroidal anti-inflammatory agent, naproxen. Am Heart J 101: 394–402PubMedCrossRefGoogle Scholar
  53. 53.
    Thiemermann C, Steinhagen-Thiessen E, Schror K (1984) Inhibition of oxygen centered free radical formation by the stable prostacyclin-mimetic Iloprost (ZK 36 374) in acute myocardial ischemia. J Cardiovasc Pharmacol 6: 365–366PubMedCrossRefGoogle Scholar
  54. 54.
    Ward PA, Till GO, Kunkel R, Beauchamp C (1983) Evidence for role of hydroxyl radical in compliment and neutrophil dependent tissue injury. J Clin Invest 72: 789–801PubMedCrossRefGoogle Scholar
  55. 55.
    Werns SW, Shea MJ, Driscoll EM, Cohen C, Abrams GD, Pitt B, Lucchesi BR (1985) The independent effects of oxygen radical scavengers on canine infarct size. Reduction by superoxide dismutase and not catalase. Circ Res 56: 895–898PubMedGoogle Scholar
  56. 56.
    Werns SW, Shea MJ, Lucchesi BR (1985) Free radicals in ischemic myocardial injury. J Free Radicals Biol Med 1: 103–110CrossRefGoogle Scholar
  57. 57.
    Wildenthal K (1978) Lysosomal alterations in ischemic myocardium: results or cause of myocellular damage? J Mol Cell Cardiol 10: 595–603PubMedCrossRefGoogle Scholar
  58. 58.
    Wildenthal K, Decker RS, Poole AR, Griffin EE, Dingle JT (1978) Sequential lysosomal alterations during cardiac ischemia. I. Biochemical and immunohistochemical changes. Lab Invest 38: 656–661PubMedGoogle Scholar
  59. 59.
    Zurier RB, Quagliata F (1971) Effects of prostaglandin El on adjuvant arthritis. Nature 234: 304PubMedCrossRefGoogle Scholar
  60. 60.
    Zurier RB, Damjanou I, Sayadoff DM, Rothfield N (1979) Prostaglandin Bu treatment of NZB/NZW Fi hybrid mice. II. Prevention of glomerulonephritis. Arthritis Rheum 20: 1449CrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1987

Authors and Affiliations

  • P. J. Simpson
    • 1
  • B. R. Lucchesi
    • 1
  1. 1.Medical School, Department of PharmacologyThe University of MichiganAnn ArborUSA

Personalised recommendations